Evidence map›Paper›PMID 35851020›Full record

Observational studyBMJ open2022

Burden of brain and other central nervous system cancer in China, 1990-2019: a systematic analysis of observational data from the global burden of disease study 2019.

Xinran Hou, Zongbin Song, Fan Zhang, Zhuoyi Liu, Wenyong Long, Zheng Long, Maigeng Zhou, E Wang, Peng Yin, Maoen Zhu

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinran HouDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zongbin SongDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Fan ZhangDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhuoyi LiuDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wenyong LongDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zheng LongNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Maigeng ZhouNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
E WangDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0001-9463-9769
Peng YinNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China zhumaoen@csu.edu.cn yinpeng@ncncd.chinacdc.cn.
Maoen ZhuDepartment of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China zhumaoen@csu.edu.cn yinpeng@ncncd.chinacdc.cn.ORCID 0000-0002-7385-1557

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the trends in disease burden and the epidemiological features of central nervous system (CNS) cancer in China from 1990 to 2019.

designA population-based observational study.

settingThe incidence, prevalence, death and disability-adjusted life years (DALYs) due to CNS cancer in China, stratified by sex, age and provincial region, were collected from the Global Burden of Disease Study 2019.

participantsData were publicly available and individuals were not involved.

resultsIn 2019, the incident cases of CNS cancer in China were 347 992 (95% UI 262 084-388 896), and the age-standardised rate (ASR) of incidence was 5.69 (95% UI 4.36-6.78) per 100 000 person-years increased by 27.9% compared with that in 1990; meanwhile, CNS cancer caused 63 527 (95% UI 47 793-76 948) deaths in China in 2019, and the ASR of death was 3.5 (95% UI 2.62-4.21) per 100 000 person-years decreased by 9.6%. The ASRs of incidence and prevalence of CNS cancer in China increased more rapidly than the global average; meanwhile, the ASRs of DALYs owing to CNS cancer declined more rapidly. The burden of CNS cancer showed no significant differences between men and women, but was more pronounced in early childhood and old adulthood. The ASRs of incidence and prevalence were higher in high-income provinces, confirmed by the positive correlation with Sociodemographic Index (SDI), with correlation coefficient r of 0.322 and 0.767, respectively (both p<0.0001). However, the ASRs of death and DALYs demonstrated a negative correlation with SDI, with r of -‍0.319 and -0.642, respectively (both p<0.0001).

conclusionsFrom a global perspective, China has been bearing a substantial burden of CNS cancer. More attention should be paid to children and elderly populations for CNS cancer. The disease burden varied significantly at the subnational level of China, which was associated with socioeconomic development.

Indexed as

Brain NeoplasmsCentral Nervous System NeoplasmsAgedChildChild, PreschoolChinaFemaleGlobal Burden of DiseaseHumansIncidenceMalePrevalenceEpidemiologyEPIDEMIOLOGYNeurological oncologyPUBLIC HEALTH

Identifiers

PMID35851020
PMCPMC9297202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.